Phaseline

Companies › Acepodia Biotech

Acepodia Biotech: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACE2016
Allogeneic gamma delta T (gdT) cell therapy engineered to target EGFR-expressing tumors
EGFRPhase 1Locally Advanced Solid TumorDec 2026
ACE1831
Allogeneic gamma delta T cell therapy
–Phase 1IgG4 Related DiseaseSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06415487ACE2016Phase 1Locally Advanced Solid TumorOncologyDec 2026
NCT07061938ACE1831Phase 1IgG4 Related DiseaseOtherSep 2029

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.